Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome.
Am J Med. 1985 Mar;78(3):417-22. Unique Identifier : AIDSLINE MED/85145918 Lane HC; Masur H; Gelmann EP; Longo DL; Steis RG; Chused T; Whalen G; Edgar LC; Fauci AS
Abstract:
The present study was designed to determine whether there was a significant correlation between the clinical presentation of patients with AIDS or AIDS-related illnesses and the degree of their underlying immunologic abnormalities. In 17 patients who presented with opportunistic infections, the mean number of T4 lymphocytes was 34/mm3 and the mean proliferative response to phytohemagglutinin 26,000 cpm; in 12 patients who presented with Kaposi's sarcoma alone, the mean number of T4 cells was 231/mm3 and the mean proliferative response to phytohemagglutinin, 32,809 cpm; and in nine patients with the lymphadenopathy syndrome, the mean number of T4 cells was 703/mm3 and the mean proliferative response to phytohemagglutinin, 49,317 cpm. These findings suggest that those patients who present with opportunistic infections as their initial clinical manifestation of AIDS may represent a subgroup with a more severe immunologic derangement prior to clinical diagnosis. Thus, in those who have a predisposition to Kaposi's sarcoma, this disease will often develop, prior to the development of T cell dysfunction, to the degree of that in those who present with opportunistic infections. This finding is of importance in attempts to understand the pathogenesis of this syndrome and in the design of therapeutic trials.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/*IMMUNOLOGY Adult Antigens/PHARMACOLOGY Cells, Cultured Comparative Study *Homosexuality Human Infection/COMPLICATIONS/IMMUNOLOGY Leukocyte Count Lymphatic Diseases/IMMUNOLOGY Lymphocyte Transformation Male Middle Age Mitogens/PHARMACOLOGY Sarcoma, Kaposi's/IMMUNOLOGY T-Lymphocytes/*CLASSIFICATION/DRUG EFFECTS/IMMUNOLOGY JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
